Published on: August 1, 2015
by Business-Standard:
A new drug to treat Alzheimer’s disease may be four times more effective than the current medication in improving the brain power of patients, Australian researchers say.
Preliminary results from the drug trial of Anavex 2-73 in Alfred Health hospital in Victoria showed that of the 12 patients in the trial, 10 had improved brain function.
Trial leader associate professor Steve Macfarlane, Caulfield Hospital director of Aged Psychiatry, said he was “cautiously optimistic” about the drug trial of Anavex 2-73 in patients with the early stage of the disease.
As part of the trial the researchers analysed the electrical activity in patient’s brains, which is a measure of cognition, ‘Herald Sun’ reported.
“This drug seems to improve electrical markers by four times more than the current standard of care drug, which is a medication called donepezil (Aricept),” Macfarlane said.
The result, which came after 36 days of therapy, is already higher than what donepezil reaches after six months of taking it continuously, researchers said.
“We’ve also had patients and their carers reporting improvements in their thinking, increased alertness and improvement in their organisation and independence,” Macfarlane said.
“It seems to be hitting the receptors that it is meant to and be having the desired result in improving brain activity,” Macfarlane said.
The final results of the study, which will involve 32 people in total, should be known by the end of the year, researchers said.
However, Macfarlane said while it was important to recognise the positive results of the trial, they were only preliminary.
The preliminary results of the study were presented at the 2015 Alzheimer’s Association International Conference (AAIC) in the US.
Source: http://bit.ly/1KHxKJe
In a new study, University of Nebraska–Lincoln sociologist Marc A. Garcia explored how educational attainment can benefit cognitive health in later life, and whether there are differences in its benefits among minorities. Garcia and his co-authors...
A genetic variation in some people may be associated with cognitive decline that can’t be explained by deposits of two key proteins associated with Alzheimer’s disease, amyloid β and tau, according to a study...
As 2020 drags on and the Covid-19 pandemic continues to ravage the world, the number of people reporting mental health issues, including anxiety, depression and stress, has skyrocketed. According to recent data, symptoms of anxiety and...
The material presented through the Think Tank feature on this website is in no way intended to replace professional medical care or attention by a qualified practitioner. WBHI strongly advises all questioners and viewers using this feature with health problems to consult a qualified physician, especially before starting any treatment. The materials provided on this website cannot and should not be used as a basis for diagnosis or choice of treatment. The materials are not exhaustive and cannot always respect all the most recent research in all areas of medicine.
